欧文原著

1. Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION
　multicenter, two-arm, open-label, randomized trial.
　　Kamata Y, Kessoku T, Shimizu T, Kobayashi T, Kurihashi T, Sato S, Kuraji S, Aoyama N, Iwasaki T, Takashiba S,
　　Hamada N, Kodama T, Tamura T, Ino S, Higurashi T, Taguri M, Yamanaka T, Yoneda M, Usuda H, Wada K, Nakajima A,
　　Minabe M.
　Trials. 21:291, 2020

2. The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered
　microbiota.
　　Noboru Misawa, Takuma Higurashi, Tomohiro Takatsu, Michihiro Iwaki, Takashi Kobayashi , Tsutomu Yoshihara,
　　Keiichi Ashikari, Takaomi Kessoku, Akiko Fuyuki, Tetsuya Matsuura, Hidenori Ohkubo, Haruki Usuda, Koichiro Wada,
　　Nakayuki Naritaka, Hajime Takei, Hiroshi Nittono, Mitsuharu Matsumoto, Akira Honda, Atsushi Nakajima,
　　Michael Camilleri.
　Alimentary Pharmacology and Therapeutics. 52:821-828, 2020

3. Recombinant human soluble thrombomodulin suppresses monocyte adhesion by reducing lipopolysaccharide-induced
　endothelial cellular stiffening
　　Takayuki Okamoto, Eiji Kawamoto, Haruki Usuda, Tetsuya Tanaka, Tetsuro Nikai, Kunihiro Asanuma, Koji Suzuki,
　　Motomu Shimaoka, Koichiro Wada
　Cells. 9:E1811, 2020